Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
Alzheimer's disease, a devastating neurological condition characterised by progressive memory loss and cognitive decline, affects millions worldwide. The profound impact extends beyond patients to their families and caregivers. While new treatments are emerging for individuals in the early stages of the disease, a critical challenge remains: the need for accessible, cost-effective, and accurate diagnostic tools to identify Alzheimer's sooner.
In a significant stride forward, Mayo Clinic researchers have validated the accuracy of an FDA-approved blood test that promises to revolutionise Alzheimer's diagnosis. This accessible test, suitable for use in outpatient memory clinics, demonstrated high accuracy in diagnosing the disease across a spectrum of cognitive impairments. The groundbreaking findings are published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Traditionally, diagnosing Alzheimer's disease has relied on methods such as positron emission tomography (PET) scans and spinal taps, which measure the buildup of toxic proteins in the brain. However, these procedures are often expensive and invasive, limiting their widespread applicability. The urgent need for more accessible, non-invasive, and cost-effective biomarkers – measurable indicators of a disease – has been a driving force in Alzheimer's research. This new blood test addresses that critical need, paving the way for improved diagnoses in diverse clinical settings.
The research team highlights the immense potential of their findings, stating that this blood test can significantly contribute to better identifying research participants with Alzheimer's disease brain changes, efficiently screening and selecting patients with Alzheimer's disease for clinical trials, and more effectively assessing patient response to therapy in clinical trials.
The study involved over 500 patients receiving treatment for various memory issues at the outpatient Memory Disorder Clinic at the Mayo Clinic in Florida. The diverse patient cohort included individuals with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia, and vascular cognitive impairment. Patients ranged in age from 32 to 89, with the average age of symptom onset at 66. Alzheimer's disease was determined to be the underlying cause of symptoms in 56% of the participants. The research team also conducted serum tests to measure kidney disease, a factor that can influence plasma biomarker concentrations.
Mayo Clinic Laboratories conducted tests for two key proteins in blood plasma associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: Aβ42/40 and p-tau217. The results revealed significantly higher levels of p-tau217 in patients diagnosed with Alzheimer's disease compared to those without the condition. Importantly, the researchers also observed that higher plasma p-tau217 concentrations were associated with impaired kidney function, underscoring the importance of considering this factor when interpreting blood test results.
Out of 509 patients, plasma p-tau217 concentrations were positive in 267 individuals. Notably, this included 233 out of 246 patients (95%) whose cognitive impairment was attributed to Alzheimer's disease, demonstrating the test's remarkable accuracy.
The study's compelling findings were prominently featured at the American Academy of Neurology Annual Meeting in April, generating significant interest within the medical community. This research builds upon a previous study by the Mayo Clinic Laboratories team, which demonstrated the utility of these blood tests in comparison to amyloid PET scans in research participants.
Looking ahead, Dr. Day, a lead researcher on the study, emphasised the next crucial steps. The team plans to evaluate blood-based testing in more diverse patient populations and in individuals with early Alzheimer's disease who may not yet exhibit cognitive symptoms. Furthermore, they aim to investigate disease-specific factors that could potentially alter biomarker accuracy in clinical trials.
This breakthrough in blood testing offers a promising future for Alzheimer's diagnosis, enabling earlier intervention, facilitating more effective clinical trials, and ultimately providing new hope for patients and their families.
Tajikistan tripled fuel imports from neighbouring Central Asian countries in July after deliveries from Russia declined sharply, underscoring how disr...
Morocco has expressed its readiness to work with Spain and other European partners to identify and return unaccompanied minors following the mass arri...
U.S. President Donald Trump said negotiations to reopen the Strait of Hormuz are progressing and suggested an agreement with Iran could be reached “...
U.S. President Donald Trump said there was an "all-day negotiation" on Tuesday with Iran, characterising the talks positively while also threatening to hit Iran "really hard" if a deal was not reached.
Shipping traffic through the Strait of Hormuz and the Bab el-Mandeb Strait, two key maritime chokepoints in the region, decreased significantly from the previous day, according to shipping data.
Start your day informed with AnewZ Morning Brief. Here are the top news stories for the 6th of August, covering the latest developments.
U.S. President Donald Trump said negotiations to reopen the Strait of Hormuz are progressing and suggested an agreement with Iran could be reached “soon”.
Kazakhstan’s main oil export corridor was disrupted by drone strikes near Russia’s Black Sea coast in July, forcing a temporary suspension of crude loadings and raising fresh concerns over the vulnerability of regional energy infrastructure to the war in Ukraine.
The Ebola outbreak in the Democratic Republic of Congo is expected to surpass 4,000 cases this week, with delayed detection, weak surveillance, funding shortages and conflict allowing the virus to spread faster than in any previous epidemic at the same stage.
Australia warned on Monday (3 August) of a wider spread of H5N1 bird flu after its first confirmed mass mortality event among seabirds killed about 50 greater crested terns off the coast of South Australia, south of Adelaide.
Cancer patients in Sudan are struggling to access life-saving treatment as soaring medication costs, power shortages and damaged hospital infrastructure deepen the country's healthcare crisis after more than three years of war.
The world risks a resurgence of the HIV epidemic after international funding fell by nearly a fifth last year, according to a new report from UNAIDS, which warned that decades of progress against the disease could be reversed without renewed global support.
A global shift towards healthier diets, more efficient farming and reduced food waste could cut greenhouse gas emissions from agriculture-related land-use change by 85% by 2050, according to a study published last week in the journal Nature.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment